Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tracy T Batchelor

Showing results (161-170 of 268) with videos related to

Pageof 27
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2015
Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-HydroxyglutarateOvidiu C Andronesi, Franziska Loebel, Wolfgang Bogner, et al.
Neuro-Oncology|May 27, 2015
A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastomaElizabeth R Gerstner, Xiaobu Ye, Dan G Duda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2007
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatmentDaniel P Cahill, Kymberly K Levine, Rebecca A Betensky, et al.
Neuro-Oncology Advances|September 8, 2022
Magnetic resonance spectroscopy outperforms perfusion in distinguishing between pseudoprogression and disease progression in patients with glioblastomaMohamed E El-Abtah, Pratik Talati, Melanie Fu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2009
Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in miceWalid S Kamoun, Carsten D Ley, Christian T Farrar, et al.
Cancer|March 17, 2020
Primary dural lymphomas: Clinical presentation, management, and outcomePhilipp Karschnia, Tracy T Batchelor, Justin T Jordan, et al.
Neuro-Oncology Advances|January 4, 2021
Vascular dysfunction promotes regional hypoxia after bevacizumab therapy in recurrent glioblastoma patientsElizabeth R Gerstner, Kyrre E Emblem, Yi-Fen Yen, et al.
Journal of Oncology Practice|January 26, 2019
Performance of a Hospital Pathway for Patients With a New Single Brain MassIsabel Arrillaga-Romany, William T Curry, Justin T Jordan, et al.
Neuro-Oncology|November 30, 2018
Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse gliomaTejus A Bale, Justin T Jordan, Otto Rapalino, et al.
Blood|July 2, 2008
CNS Hodgkin lymphomaElizabeth R Gerstner, Lauren E Abrey, David Schiff, et al.
Pageof 27

Showing results (161-170 of 268) with videos related to

Sort By:
Pageof 27
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2015
Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-HydroxyglutarateOvidiu C Andronesi, Franziska Loebel, Wolfgang Bogner, et al.
Neuro-Oncology|May 27, 2015
A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastomaElizabeth R Gerstner, Xiaobu Ye, Dan G Duda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2007
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatmentDaniel P Cahill, Kymberly K Levine, Rebecca A Betensky, et al.
Neuro-Oncology Advances|September 8, 2022
Magnetic resonance spectroscopy outperforms perfusion in distinguishing between pseudoprogression and disease progression in patients with glioblastomaMohamed E El-Abtah, Pratik Talati, Melanie Fu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2009
Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in miceWalid S Kamoun, Carsten D Ley, Christian T Farrar, et al.
Cancer|March 17, 2020
Primary dural lymphomas: Clinical presentation, management, and outcomePhilipp Karschnia, Tracy T Batchelor, Justin T Jordan, et al.
Neuro-Oncology Advances|January 4, 2021
Vascular dysfunction promotes regional hypoxia after bevacizumab therapy in recurrent glioblastoma patientsElizabeth R Gerstner, Kyrre E Emblem, Yi-Fen Yen, et al.
Journal of Oncology Practice|January 26, 2019
Performance of a Hospital Pathway for Patients With a New Single Brain MassIsabel Arrillaga-Romany, William T Curry, Justin T Jordan, et al.
Neuro-Oncology|November 30, 2018
Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse gliomaTejus A Bale, Justin T Jordan, Otto Rapalino, et al.
Blood|July 2, 2008
CNS Hodgkin lymphomaElizabeth R Gerstner, Lauren E Abrey, David Schiff, et al.
Pageof 27